CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
6-Mercaptopurine +1 moredrug
Likely dose
6-Mercaptopurine 55mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01432145
NCT01432145Phase 2Completed
CompareCT.gov

Phase II Clinical Trial Of 6-Mercaptopurine (6MP) and Low-Dose Methotrexate In Patients With Known BRCA Defective Tumours

University of Oxford·interventional·Posted Sep 12, 2011·Updated Jul 9, 2019

In Brief

A Phase 2 clinical trial evaluating 6-Mercaptopurine and Methotrexate for Breast Cancer and Ovarian Cancer. Completed, enrolled 74 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a BRCA (breast cancer gene) mutation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Ovarian Cancer
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2011
Enrollment StartMay 1, 2011
Primary CompletionDec 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.8 years ago

Interventions

6-Mercaptopurinedrug

6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.

Methotrexatedrug

Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.